Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Patent Office has granted India-based Suven Life Sciences two patents for the treatment of neurodegenerative diseases. The patents are valid until June 2022.
Subscribe to our email newsletter
The granted claims of the patent include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s, attention deficient hyperactivity, Huntington’s disease, Parkinson’s disease and schizophrenia.
Suven has three European patents granted until now and all of them have been validated in all the 37 member countries of Europe.
Venkat Jasti, CEO of Suven, said: “We continue to work on G-Protein coupled receptor targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential.”